Recurrent migraine: cost-effective care
Abstract
The cost of untreated or ineffectively treated migraine is staggering. A case study is presented that demonstrates the importance of developing an individually tailored home treatment program for migraine patients aimed at keeping them out of healthcare facilities on an acute basis. Treatment programs should include preventive medications if attacks occur more than twice per month, as well as appropriate abortive and symptomatic agents in the event of a severe, acute migraine attack. New agents and treatment modalities are making acute treatment more cost-effective and making it less likely that unnecessary time be spent seeking medical help at the time of an attack.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.